Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.

ESMO Open · 2024 · PMC11415680 · PMID 39255538

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significanceP = 0.06so close (0.05 < p ≤ 0.1)

According to the treatment regimen, we observed a trend toward a better DCR and improved OS with the triplet regimen, although this did not reach statistical significance (DCR: 85.7% versus 69.2%, P = 0.06; median OS: 12.3 months versus 9.1 months with the doublet, P = 0.20).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.